Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Telix Pharmaceuticals Ltd Director's Dealing 2017

Nov 14, 2017

31324_rns_2017-11-14_8f1dbd5a-2f35-4e7b-9f12-0100d51e8d5e.pdf

Director's Dealing

Open in viewer

Opens in your device viewer

Appendix 3X Initial Director’s Interest Notice

Rule 3.19A.1

Appendix 3X

Initial Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/9/2001.

Name of entity Telix Pharmaceuticals Limited ABN 85 616 620 369

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director Mark Alexander Nelson
Date of appointment 17 September 2017

Part 1 - Director’s relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Number & class of securities

990,000 unlisted share options with an exercise price of $0.85 per option and an expiry date of 14 October 2021, granted subsequent to shareholder approval at the EGM held 13 October 2017.

  • See chapter 19 for defined terms.

Appendix 3X Page 1

11/3/2002

Appendix 3X Initial Director’s Interest Notice

Part 2 – Director’s relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of
interest
Note: Provide details of the circumstances giving rise to
the relevant interest.
MAN Holdings Pty Ltd, as Trustee
for The Nelson Hybrid Trust, of
which Mark Nelson is a director
and shareholder.
Number & class of Securities
2,238,750 fully paid ordinary shares, of which
770,000 shares were acquired in the Initial Public
Offering of the Company at a price of $0.65 per
share.

Part 3 – Director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract Not applicable
Nature of interest
Name of registered holder
(if issued securities)
No. and class of securities to which
interest relates
  • See chapter 19 for defined terms.

Appendix 3X Page 2

11/3/2002